High-Sensitivity Immunodiagnostics (Digital ELISA)

Prostate Cancer Recurrence Monitoring

Alzheimer's Disease (AD)

Many proteins thought to be potential diagnostic markers of human diseases, including cancer, autoimmune, and cardiovascular disease, circulate at concentrations well below the limits of detection of current protein detection technologies, such as ELISA. More sensitive methods for detecting proteins in blood are needed to bridge the gap between circulating concentrations and limits of detection. Utilizing SiMoA, improvements in analytical sensitivity of more than 1000-fold over ELISA have already been demonstrated for a number of serum proteins of interest to the medical community.

Quanterix believes that by offering the highest sensitivity and best precision over a wide dynamic range, its SiMoA platform has the potential to become an industry standard. To demonstrate the value and robustness of SiMoA, Quanterix is establishing a CLIA compliant laboratory and will initially focus on two diagnostic test markets. These markets were selected because there is a major unmet medical need and candidate biomarkers are known, but currently cannot be adequately measured in blood. Over the longer term, the company will partner with life science researchers developing novel biomarkers and leverage its sensitivity advantage to translate proteomic and expression array-based research into serum-based diagnostic tests.